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Abstract 
 
Background The EUROASPIRE cross-sectional surveys describe time trends in 
lifestyle and risk factor control among coronary patients between 1999 and 2013 in 
Belgium, Czech Republic, Finland, France, Ireland, The Netherlands, Poland, 
Slovenia and the United Kingdom as part of the EuroObservational Research 
Programme under the auspices of European Society of Cardiology. 
Objectives To describe time trends in lifestyle, risk factor control and the use of 
evidence-based medication in coronary patients across Europe.  
Methods The EUROASPIRE II (1999-2000), III (2006-2007) and IV (2012-13) 
surveys were conducted in the same geographical areas and selected hospitals in each 
country. Consecutive patients (≤70 years) after CABG, PCI or an acute coronary 
syndrome identified from hospital records were interviewed and examined ≥6 months 
later with standardized methods. 
Results Of 12,775 identified coronary patients 8456 (66.2%) were interviewed. 
Proportion of current smokers was similar across the three surveys. Prevalence of 
obesity increased by 7%. The prevalence of raised blood pressure (≥140/90 mmHg or 
≥140/80 mmHg with diabetes) dropped by 8% from III to IV, and therapeutic control 
of blood pressure improved with 55% of patients below target in IV. The prevalence 
of LDL-C≥2.5 mmol/l decreased by 44%. 75% were above the target LDL-C<1.8 
mmol/l in IV. The prevalence of self reported diabetes increased by 9%. The use of 
evidence-based medications increased between II and III surveys but did not change 
between III and IV surveys.  
Conclusions Lifestyle habits have deteriorated over time with increases in obesity, 
central obesity and diabetes and stagnating rates of persistent smoking. Although 
blood pressure and lipid management improved they are still not optimally controlled 
and the use of evidence-based medications appears to have stalled apart from the 
increased use of high intensity statins. These results underline the importance of 
offering coronary patients access to modern preventive cardiology programmes.  
 
Key words: EUROASPIRE, coronary patients, prevention, guideline implementation 
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EUROASPIRE = EUROpean Action on Secondary and Primary prevention In order 
the Reduce Events 
CVD = cardiovascular disease 
SBP = systolic blood pressure 
DBP = diastolic blood pressure 
MI = Myocardial Infarction  
LDL-C = low-density lipoprotein cholesterol 
BMI = body mass index 
ACE = angiotensin-converting enzyme  
ARBs = angiotensin-receptor blockers 
WHO = World Health Organisation 
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Introduction 
 
In 2012 the 194 World Health Organisation (WHO) member states adopted a global 
target to reduce premature mortality from non-communicable diseases (NCDs) by 
25% by 2025 (1). Cardiovascular disease (CVD) accounts for a majority of NCDs 
mortality and is preventable. The WHO adopted targets to achieve this ambition 
embracing lifestyle, risk factors and the use of essential medicines and technologies, 
including preventive and rehabilitative care for those with established CVD. Since 
1996 the EUROASPIRE (European Action on Secondary and Primary Prevention by 
Intervention to Reduce Events) surveys have described the management of coronary 
patients using comparable methodologies over time (2-8). The same nine countries 
participated in EUROASPIRE II  (1999-2000) (3), EUROASPIRE III (2007-2008) (5) 
and EUROASPIRE IV (2012-2013) (7,8). These three surveys included a total of 
12,775 consecutive patients with established coronary artery disease of whom 8,456 
were interviewed at least six months after their initial hospitalisation and form the 
basis for 14-year time trend analyses in lifestyle and therapeutic management 
compared to targets set by the most recent Joint European Societies Cardiovascular 
Prevention Guidelines in Clinical Practice (9). The comparison between 
EUROASPIRE I, II and III surveys showed an increase in obesity, no change in 
smoking and poor blood pressure and lipids control despite the substantial increase in 
blood pressure and lipid-lowering drugs. In EUROASPIRE IV, we looked at the 
lifestyle and medical risk factors and the use of evidence-based medication as it was 
important to determine whether the adverse lifestyle and risk factors time trends 
continued and whether the practice of preventive cardiology has improved by 
comparison with the previous surveys.  
 
 
Methods 
 
Study design 
 
EUROASPIRE II, III and IV were cross-sectional surveys conducted from 1999-2013 
in Belgium, the Czech Republic, Finland, France, Ireland, the Netherlands, Poland, 
Slovenia and United Kingdom. The surveys were undertaken in the same 
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geographical areas including at least one hospital offering interventional cardiology and 
cardiac surgery, and one or more acute hospitals receiving patients with acute 
myocardial infarction (MI) and unstable angina. A sample of hospitals was taken in such 
a way that any patient presenting within the geographical area with acute symptoms of 
coronary disease, or requiring revascularisation in the form of balloon angioplasty or 
coronary artery surgery, had an approximately equal chance of being included in the 
patient sample. Countries where the surveys were undertaken in different areas were 
excluded. The number of centres in the three surveys was 26, 27 and 32 respectively, 
from the same geographical areas.   
 
Study population  
 
Consecutive patients, men or women [≥18 years and <70 years at the time of 
identification], with first or recurrent clinical diagnosis for coronary heart disease (see 
below) were retrospectively identified from diagnostic registers, hospital discharge 
lists or other sources: (i) coronary artery bypass grafting, (ii) percutaneous coronary 
intervention, (iii) acute MI, and (iv) unstable angina. The starting date for 
identification was >6 months ≤3 years prior to the study interview.  
 
Data collection 
 
Information on personal and demographic details, self reported lifestyle and 
medication was obtained at interview. Central training of data collectors ensured 
quality of data collection according to a written protocol, using standardised 
methodologies for all measurements, equipment calibrated according to the 
manufacturer’s recommendations, and a central laboratory for total and HDL-
cholesterol and triglycerides (see appendix). The LDL-C concentration was calculated 
using Friedewald’s formula in all surveys (13). 
 
Statistical analyses 
 
A total of 2,100 interviewed patients were required from each of the three 
EUROASPIRE surveys to demonstrate differences in prevalence of at least 5% 
between surveys with 90% power at the 0.05 significance level. Frequency of risk 
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factors, lifestyles and drug use by survey, country, gender and age at interview are 
therefore reported at a European level only using descriptive statistics. Clustering of 
patients within centres was taken into account using multilevel modelling. A random 
coefficient model allowed for variation in time trends of risk factor frequencies 
between countries. P-values for evaluating the null hypothesis of equality in risk 
factor frequencies between surveys were based on Wald-type tests. Tukey’s method 
for correcting P-values and confidence intervals was used to account for multiplicity 
in pairwise comparisons of surveys. Potential confounding due to differences in 
distributions of age and gender between surveys was adjusted for in all models. All 
statistical analyses were done with SAS statistical software (version 9.3). 
 
Results  
 
Patient characteristics 
 
12,775 patients were consecutively identified and 8,456 interviewed (66.2%): 3,320 
patients in EUROASPIRE II (1999-2000), 2,632 in EUROASPIRE III (2006-2007) 
and 2,513 in EUROASPIRE IV (2012-13) (Table 1). Interview rates were 67.5%, 
63.6% and 51.4% respectively, slightly lower in females and those aged ≥60 years.  A 
comparison of those attending for interview with those who did not showed that the 
interview participation rate was lower in women, in younger patients (except 
EUROASPIRE II), for those with acute myocardial infarction or unstable angina not 
revascularised. Median (interquartile range) times between the index event and 
interviews for the three surveys were 1.45(1.14-1.90), 1.22(0.98-1.63) and 1.39(1.00-
1.92) years. The trends in lifestyle, risk factors and medications, stratified by the time 
between recruiting event and interview (less or more than the median of 1.3 years), 
were very similar for all variables.  None of the two-way interactions between survey 
and time between recruiting event and interview was significant at P=0.10 level. 
 
Study outcomes 
 
The prevalence of current smoking, defined as the proportion of all patients smoking 
at the time of interview, did not differ across the surveys, with the highest rates in 
youngest (<50 years) patients, in both men and women (Table 2a). About half of 
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patients were persistent smokers having reported they were smoking in the month 
prior to their index event and still smoking at the time of interview. Among these 
smokers a large majority (81.4%, 67.4%, 72.5%; p=0.19) had attempted to quit 
following their coronary event. The use of pharmacotherapy for smoking cessation 
was low and did not change over time. 
 
There was no change in the level of leisure time physical activity. Proportions 
of patients reaching recommended levels (vigorous physical activity for at least 20 
minutes once or more times a week) were 37.3%, 33.8% and 41.8%; p=0.78) across 
the three surveys. 
 
Prevalence of overweight did not differ across the surveys (Table 2b). 
However, prevalence of obesity increased from 31.9% in EUROASPIRE II to 38.5% 
in EUROASPIRE IV (p=0.007) with the greatest difference between survey III and 
IV. The same trend was observed for central obesity. 
 
Prevalence of raised blood pressure dropped from 53.5% to 44.5% (p=0.01) 
between EUROASPIRE II and EUROASPIRE IV. The prevalences of very high 
blood pressure (systolic≥160 mmHg and/or diastolic≥100 mmHg) also dropped 
(21.9%, 16.8% and 12.8%; p=0.0006). Therapeutic control of blood pressure in 
patients using blood pressure lowering drugs improved with 55% of patients below 
target in EUROASPIRE IV (Table 3a).  
 
The prevalence of raised total cholesterol decreased using either ≥4.5 mmol/l 
(77.0%, 40.6%, 32.8%; p<0.0001) or ≥4.0 mmol/l (89.3%, 62.6%, 54.3%; p<0.0001) 
as cut-points, and so did the prevalence of elevated LDL-C≥2.5 mmol/l (78.0%, 
42.9%, 33.5%; p<0.0001). Using ≥1.8 mmol/l to define elevated LDL-C the decline 
over time is also present with 75.3% of patients being above the target <1.8 mmol/l in 
the most recent survey. Among all patients treated with lipid lowering drugs the 
proportion with LDL-C<1.8 mmol/l increased by 20% between survey II and IV 
(Table 3b). Although the proportion of patients on lipid-lowering drugs was similar 
between EUROASPIRE III and IV the use of high intensity statins (Atorvastatin 
40-80mg or Rosuvastatin 20-40mg or Simvastatin 80mg) increased from 23.0% to 
45.1%. 
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The prevalence of self reported diabetes increased (18.5%, 23.8% to 27.2%; 
p=0.004).  
 
The use of evidence-based medications in the surveys is described in Tables 
4a and 4b. The frequency of evidence-based medications use increased between 
EUROASPIRE II and III but did not change between EUROASPIRE III and IV 
surveys.  
 
Discussion 
 
The EUROASPIRE cross-sectional surveys undertaken on three occasions over a 
period of 14 years describe time trends in risk factor control and use of evidence-
based medications among coronary patients. Lifestyle factors are deteriorating with 
increasing prevalences of obesity and central obesity and corresponding increases in 
the prevalence of diabetes mellitus. The control of blood pressure and LDL-C has 
improved over this period but most patients have still not achieved the guideline 
targets.  The proportion of patients on evidence-based medications did not change 
between 2006 and 2013 although the use of high-intensity statins almost doubled. By 
comparison with standards set in the European guidelines on CVD prevention there is 
still considerable potential to reduce the risk of recurrent disease and improve 
survival. 
 
There is a wealth of scientific evidence from meta-analyses of randomised 
controlled trials and observational studies that secondary prevention and cardiac 
rehabilitation are effective in reducing both cardiovascular and total mortality (11-14). 
The comprehensive, multifactorial approach to reduce total cardiovascular risk is 
strongly underlined in European and US guidelines on cardiovascular prevention 
(9,15). Recent studies such as EUROACTION and GOSPEL provide scientific 
evidence that structured, multidisciplinary programmes achieve healthier lifestyles 
and more effective risk factor control compared to usual care (16,17). In contrast the 
reality of cardiac rehabilitation provision, as described in EUROASPIRE III, varies 
widely. Only 45% of the patients were advised to attend and only 36% of those 
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eligible participated (18). These patients had by comparison to non-participants, 
improved lifestyle and risk factor management after one year. A health economics 
analysis from EUROASPIRE III showed that preventive care for coronary patients is 
cost effective for different health economies across Europe (19). Yet, despite the 
evidence for cost effectiveness the results of the European Cardiac Rehabilitation 
Inventory Survey show that provision of high quality services is limited because of 
lack of government funding, no professional guidelines or health service 
infrastructure (20).   
 
The EUROASPIRE surveys show that the prevalence of persistent smokers 
did not change over the years but, importantly, that most smokers attempt to quit after 
their coronary event indicating a genuine wish to do so. This intention is more likely 
to be successful if supported by a smoking cessation specialist using evidence-based 
pharmacotherapy (21,22). Yet only a minority of the participants in EUROASPIRE 
received support and drugs for smoking cessation.  
 
	 Obesity and central obesity have increased together with diabetes mellitus 
across the three surveys with an increased risk of recurrent macrovascular disease, 
microvascular disease and further reduction in life expectancy. In a mortality follow-
up of the EUROASPIRE I cohort of 5,216 coronary patients the independent 
modifiable risk factors associated with an increased risk of dying were smoking, 
cholesterol and poor glucose control (23). The potential to reduce that risk in diabetes 
is considerable by combining lifestyle and risk factors control and evidence-based 
medications (24,25). 	
In contrast blood pressure and lipid control are improving although many 
patients are still not achieving the targets set in the current 2012 Joint European 
Societies Guidelines on CVD Prevention despite high prescription rates for evidence-
based medications. These rates are comparable to trial populations such as the 
REACH registry and the STABILITY study, but considerably higher than the PURE 
study including the high-income countries (26-28). Yet, there appears to be a ceiling 
to prescribing with no increase in the proportions of patients on any of the blood 
pressure or lipid lowering drugs between EUROASPIRE III and IV. However, the 
progress was being made, as there was a two-fold increase in the proportion of 
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patients on high intensity statins between EUROASPIRE III and IV. The next steps 
for reducing the risk of recurrent disease could be by optimizing the dose of evidence-
based medications and improving patient adherence.  
 
By comparison with earlier multinational studies in Europe and the United 
States   the prevalence and control of cardiovascular risk factors is comparable. (29-
32). The nine-year trends (1998-2006) in achievement of risk factor goals in patients 
with cardiovascular disease showed that adherence to guidelines was suboptimal and 
lower in Europe than in the United States (29). In patients with CVD and diabetes 
type 2 NHANES reported significant improvements in blood pressure, LDL-
cholesterol and triglycerides but only modest improvements in lifestyle factors.  
 
Strengths and limitations 
The EUROASPIRE surveys are conducted in selected geographic regions which are 
not nationally representative  and the centres selected within each region include at 
least one offering interventional cardiology and cardiac surgery but not necessarily all 
centres. Therefore there is a conservative bias because the reality of secondary 
prevention practice outside these specialist centres will be poorer than described by 
EUROASPIRE. The interview rates across all three surveys combined was 66% but 
this is not a true participation rate as it was not possible to identify all those who had 
moved away or died and these patients are still included in the denominator. The 
falling interview rate may reflect falling participation in medical research generally 
(33), for which there are many reasons including increasing restrictions by ethics 
committees on how patients are recruited, and patients less willing to volunteer. 
However, this introduces a similar conservative bias because non-responders are more 
likely to be persistent smokers with unhealthier diets and an even more sedentary 
lifestyle. This is supported by a comparison of patient characteristics at hospital 
discharge in those who attended for interview with those who did not in the countries 
participated in EUROASPIRE IV. The interview participation rate was significantly 
lower in women, in smokers and in those with abnormal glucose metabolism (7). 
Therefore the evidence-practice gap between guideline recommendations for lifestyle, 
medical risk factors and evidence-based medications and patient management 
described by these EUROASPIRE surveys is likely to be much wider.  
 
 12 
Conclusions 
 
The adverse lifestyle factors trends described by the EUROASPIRE surveys in 
patients surviving the development of coronary disease, characterised by high levels 
of persistent smoking and inexorable increases in obesity, central obesity and 
diabetes, will mitigate to some extent the gains made in improving blood pressure and 
lipid control. The progress with lipids management and the use of evidence-based 
medications that has been made since 1999 has slowed down in the past five years. A 
modern preventive cardiology programme could bring together all elements of 
‘cardiac rehabilitation’ and ‘secondary prevention’ to deliver one comprehensive 
service addressing all aspects of lifestyle, medical risk factor control and prescription 
of, and adherence with, evidence-based medications. All cardiovascular patients 
should be guaranteed access to modern preventive cardiology programmes in every 
country in order to gain, beyond those initial life saving treatments, longer, healthier 
and productive lives. 
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Appendix A. Data collection and data management 
 
 
Data Collection 
 
Measurements were made with the following instruments: 
a) Height and weight in light indoor clothes without shoes (SECA scales and 
measuring stick, model number 707 in EUROASPIRE II and SECA scales 
701 and measuring stick model 220 in EUROASPIRE III and IV). Overweight 
was defined as a body mass index (BMI)≥25 kg/m2 and obesity as a BMI≥30 
kg/m2. 
b) Waist circumference was measured using a metal tape applied horizontally at 
the point midway in the mid-axillary line between the lowest rim of the rib 
cage and the tip of the hip bone (superior iliac crest) with the patient standing. 
Central obesity was defined as a waist circumference of ≥88 cm for women 
and ≥102 cm for men. 
c) Blood pressure was measured twice on the right upper arm in a sitting position 
using an automatic digital sphygmomanometers (Omron 711 in 
EUROASPIRE II, Omron M5-I in EUROASPIRE III and Omron M6 in 
EUROASPIRE IV) and the mean was used for all analyses. Raised blood 
pressure was defined as systolic blood pressure (SBP)≥140 mmHg and/or 
diastolic blood pressure (DBP)≥90 mmHg in patients with no diabetes, and 
SBP≥140 mmHg and/or DBP≥80 mmHg in patients with diabetes. 
d) Breath carbon monoxide was measured in ppm using a smokerlyser (Bedfont 
Scientific, Model EC50 in EUROASPIRE II, Bedfont Scientific, Model 
Micro4 in EUROASPIRE III and Bedfont Scientific, Model Micro+ in 
EUROASPIRE IV). Smoking at the time of interview was defined as self-
reported smoking and/or a breath carbon monoxide exceeding 10 ppm. 
Persistent smoking was defined as smoking at interview among patients who 
reported smoking in the month prior to the index event.  
e) Venous (fasting) blood was drawn for serum total and HDL-cholesterol and 
triglycerides. Elevated LDL-cholesterol (LDL-C) concentration was defined 
as ≥1.8 mmol/l (70 mg/dl) 
f) Leisure time physical activity was assessed with the following question: 
Which of the following four best describes your level of activity outside 
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work? (i) no physical activity weekly; (ii) only light physical activity in most 
weeks; (iii) vigorous physical activity at least 20 minutes once or twice a 
week; (iv) vigorous physical activity for at least 20 minutes three or more 
times a week.  
 
The monitors in EUROASPIRE II (Omron 711) and III (Omron M5-I) were 
compared in 100 patients and blood pressures from survey II had to be adjusted: 
corrected SBP = observed SBP - 0.95 mmHg; corrected DBP = observed DBP + 1.42 
mmHg. According to the manufacturer no conversion formula is required for 
measurements obtained by Omron M6 and Omron M5-I.   
 
In EUROASPIRE II, serum from venous blood was used for lipid 
measurements.  The samples were stored at ≤-20°C. Total cholesterol measurements 
were performed at the Department of Medicine, University of Manchester, UK on a 
Cobas Mira S auto-analyser (Roche Diagnostics) using Unimate 7 (Roche) cholesterol 
reagent. The coefficient of variation for total cholesterol was 1.2% during the study. 
In EUROASPIRE III and IV serum from venous samples were stored at -70°C. Total 
cholesterol was measured at the central laboratory at the Disease Risk Unit, National 
Institute for Health and Welfare, Helsinki, Finland on a clinical chemistry analyser 
(Architect c8000, Abbott Laboratories, Abbott Park, Illinois, USA using enzymatic 
method for measuring).  Since the methods used for cholesterol measurement in 
EUROASPIRE II and III differed, the performance of the methods was compared by 
re-measuring a total of 183 samples from EUROASPIRE II in the EUROASPIRE III 
central laboratory and no significant difference was found (mean difference 0.011 
mmol/l, 95%CI -0.050 to +0.029) between these laboratories. Data from the external 
quality assessment programs demonstrated no systematic error in the cholesterol 
method during the study. 
 
Self reported diabetes at interview was based on a history of diabetes 
diagnosed by a physician.  
 
Written, informed consent was obtained from each patient and the study 
protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as 
reflected in a priori approval by the institution's ethics research committee.  
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Data management 
 
In EUROASPIRE II, all data were stored electronically using a unique identification 
number for country, centre and individual. Data from each country was transferred to 
the Co-ordinating Centre (Cardiovascular Medicine, National Heart and Lung 
Institute, Imperial College London, UK). In EUROASPIRE III and IV data were also 
collected electronically and submitted via Internet to the data management centre at 
European Heart House, Sophia Antipolis, France. Data were checked for 
completeness, internal consistency and accuracy. All data were stored under the 
provisions of the National Data Protection Regulations. 
 
 
